Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Sergey Menis"'
Autor:
Allan C. deCamp, Martin M. Corcoran, William J. Fulp, Jordan R. Willis, Christopher A. Cottrell, Daniel L. V. Bader, Oleksandr Kalyuzhniy, David J. Leggat, Kristen W. Cohen, Ollivier Hyrien, Sergey Menis, Greg Finak, Lamar Ballweber-Fleming, Abhinaya Srikanth, Jason R. Plyler, Farhad Rahaman, Angela Lombardo, Vincent Philiponis, Rachael E. Whaley, Aaron Seese, Joshua Brand, Alexis M. Ruppel, Wesley Hoyland, Celia R. Mahoney, Alberto Cagigi, Alison Taylor, David M. Brown, David R. Ambrozak, Troy Sincomb, Tina-Marie Mullen, Janine Maenza, Orpheus Kolokythas, Nadia Khati, Jeffrey Bethony, Mario Roederer, David Diemert, Richard A. Koup, Dagna S. Laufer, Juliana M. McElrath, Adrian B. McDermott, Gunilla B. Karlsson Hedestam, William R. Schief
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-13 (2024)
Abstract Vaccine priming immunogens that activate germline precursors for broadly neutralizing antibodies (bnAbs) have promise for development of precision vaccines against major human pathogens. In a clinical trial of the eOD-GT8 60mer germline-targ
Externí odkaz:
https://doaj.org/article/2e580eabca0b4c0f8e97acb243086a89
Autor:
Vaneet K. Sharma, Sergey Menis, Evan T. Brower, Eddy Sayeed, Jim Ackland, Angela Lombardo, Christopher A. Cottrell, Jonathan L. Torres, Thomas Hassell, Andrew B. Ward, Vadim Tsvetnitsky, William R. Schief
Publikováno v:
Pharmaceutics, Vol 16, Iss 6, p 742 (2024)
We describe the current Good Manufacturing Practice (cGMP) production and subsequent characterization of eOD-GT8 60mer, a glycosylated self-assembling nanoparticle HIV-1 vaccine candidate and germline targeting priming immunogen. Production was carri
Externí odkaz:
https://doaj.org/article/a5c660dbcce146b78053fb5ed221bb13
Autor:
Ziyang Xu, Megan C. Wise, Neethu Chokkalingam, Susanne Walker, Edgar Tello‐Ruiz, Sarah T. C. Elliott, Alfredo Perales‐Puchalt, Peng Xiao, Xizhou Zhu, Ruth A. Pumroy, Paul D. Fisher, Katherine Schultheis, Eric Schade, Sergey Menis, Stacy Guzman, Hanne Andersen, Kate E. Broderick, Laurent M. Humeau, Kar Muthumani, Vera Moiseenkova‐Bell, William R. Schief, David B. Weiner, Daniel W. Kulp
Publikováno v:
Advanced Science, Vol 7, Iss 8, Pp n/a-n/a (2020)
Abstract Nanotechnologies are considered to be of growing importance to the vaccine field. Through decoration of immunogens on multivalent nanoparticles, designed nanovaccines can elicit improved humoral immunity. However, significant practical and m
Externí odkaz:
https://doaj.org/article/a5cfd50706de4598866740c702c06b33
Autor:
Liwei Cao, Matthias Pauthner, Raiees Andrabi, Kimmo Rantalainen, Zachary Berndsen, Jolene K. Diedrich, Sergey Menis, Devin Sok, Raiza Bastidas, Sung-Kyu Robin Park, Claire M. Delahunty, Lin He, Javier Guenaga, Richard T. Wyatt, William R. Schief, Andrew B. Ward, John R. Yates, Dennis R. Burton, James C. Paulson
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-14 (2018)
HIV envelope (Env) is a potential vaccine antigen and its N-glycans are part of the epitope of broadly neutralizing antibodies. Here, the authors show that glycosylation of Env from infectious virus closely matches Env from recombinant membrane-bound
Externí odkaz:
https://doaj.org/article/4f20b420b7274e21b3fd2be2a1aa131b
Autor:
Liwei Cao, Jolene K. Diedrich, Daniel W. Kulp, Matthias Pauthner, Lin He, Sung-Kyu Robin Park, Devin Sok, Ching Yao Su, Claire M. Delahunty, Sergey Menis, Raiees Andrabi, Javier Guenaga, Erik Georgeson, Michael Kubitz, Yumiko Adachi, Dennis R. Burton, William R. Schief, John R. Yates III, James C. Paulson
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-13 (2017)
The analysis of site-specific glycosylation of HIV Envelope glycoprotein (Env) is challenging as it contains 25–30 glycosylation sites with multiple glycan forms at each site. Here the authors present a generally applicable mass spectrometry-based
Externí odkaz:
https://doaj.org/article/b94d469c8f5c4c89a79f2c9ed20be9ab
Autor:
Laura E. McCoy, Marit J. van Gils, Gabriel Ozorowski, Terrence Messmer, Bryan Briney, James E. Voss, Daniel W. Kulp, Matthew S. Macauley, Devin Sok, Matthias Pauthner, Sergey Menis, Christopher A. Cottrell, Jonathan L. Torres, Jessica Hsueh, William R. Schief, Ian A. Wilson, Andrew B. Ward, Rogier W. Sanders, Dennis R. Burton
Publikováno v:
Cell Reports, Vol 16, Iss 9, Pp 2327-2338 (2016)
A major advance in the search for an HIV vaccine has been the development of a near-native Envelope trimer (BG505 SOSIP.664) that can induce robust autologous Tier 2 neutralization. Here, potently neutralizing monoclonal antibodies (nAbs) from rabbit
Externí odkaz:
https://doaj.org/article/09f2ea3c7ca141e5bab551d53ed4a4e4
Autor:
Ema T Crooks, Samantha L Grimley, Michelle Cully, Keiko Osawa, Gillian Dekkers, Kevin Saunders, Sebastian Rämisch, Sergey Menis, William R Schief, Nicole Doria-Rose, Barton Haynes, Ben Murrell, Evan Mitchel Cale, Amarendra Pegu, John R Mascola, Gestur Vidarsson, James M Binley
Publikováno v:
PLoS Pathogens, Vol 14, Iss 5, p e1007024 (2018)
The extensive glycosylation of HIV-1 envelope (Env) glycoprotein leaves few glycan-free holes large enough to admit broadly neutralizing antibodies (bnAb). Consequently, most bnAbs must inevitably make some glycan contacts and avoid clashes with othe
Externí odkaz:
https://doaj.org/article/07efec52348049c5a19cfd97bdec12dd
Autor:
Ema T Crooks, Tommy Tong, Bimal Chakrabarti, Kristin Narayan, Ivelin S Georgiev, Sergey Menis, Xiaoxing Huang, Daniel Kulp, Keiko Osawa, Janelle Muranaka, Guillaume Stewart-Jones, Joanne Destefano, Sijy O'Dell, Celia LaBranche, James E Robinson, David C Montefiori, Krisha McKee, Sean X Du, Nicole Doria-Rose, Peter D Kwong, John R Mascola, Ping Zhu, William R Schief, Richard T Wyatt, Robert G Whalen, James M Binley
Publikováno v:
PLoS Pathogens, Vol 11, Iss 5, p e1004932 (2015)
Eliciting broad tier 2 neutralizing antibodies (nAbs) is a major goal of HIV-1 vaccine research. Here we investigated the ability of native, membrane-expressed JR-FL Env trimers to elicit nAbs. Unusually potent nAb titers developed in 2 of 8 rabbits
Externí odkaz:
https://doaj.org/article/65b7f896418649c1899f642d72673ccb
Autor:
Paul T Edlefsen, Morgane Rolland, Tomer Hertz, Sodsai Tovanabutra, Andrew J Gartland, Allan C deCamp, Craig A Magaret, Hasan Ahmed, Raphael Gottardo, Michal Juraska, Connor McCoy, Brendan B Larsen, Eric Sanders-Buell, Chris Carrico, Sergey Menis, Gustavo H Kijak, Meera Bose, RV144 Sequencing Team, Miguel A Arroyo, Robert J O'Connell, Sorachai Nitayaphan, Punnee Pitisuttithum, Jaranit Kaewkungwal, Supachai Rerks-Ngarm, Merlin L Robb, Tatsiana Kirys, Ivelin S Georgiev, Peter D Kwong, Konrad Scheffler, Sergei L Kosakovsky Pond, Jonathan M Carlson, Nelson L Michael, William R Schief, James I Mullins, Jerome H Kim, Peter B Gilbert
Publikováno v:
PLoS Computational Biology, Vol 11, Iss 2, p e1003973 (2015)
The RV144 clinical trial showed the partial efficacy of a vaccine regimen with an estimated vaccine efficacy (VE) of 31% for protecting low-risk Thai volunteers against acquisition of HIV-1. The impact of vaccine-induced immune responses can be inves
Externí odkaz:
https://doaj.org/article/3c48e8cc0f7048819758a015ac56625a
Autor:
Gözde Isik, Nancy P Y Chung, Thijs van Montfort, Sergey Menis, Katie Matthews, William R Schief, John P Moore, Rogier W Sanders
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e67309 (2013)
Broadly neutralizing antibodies (bNAbs) that target the HIV-1 envelope glycoproteins (Env) can prevent virus acquisition, but several Env properties limit its ability to induce an antibody response that is of sufficient quantity and quality. The immu
Externí odkaz:
https://doaj.org/article/7c0462fb0cb547f180f4dedadfc19894